Answers are grounded in this paper and cite their sources.
Clinical evaluation demonstrates the De Ritis ratio serves as a significant prognostic factor in myelodysplastic syndrome, suggesting its utility for risk assessment.
Background: The aspartate transaminase (AST)/alanine transaminase (ALT) ratio, also termed the De Ritis ratio, has been demonstrated to have an association with poor prognosis in several cancer types. However, its prognostic value in patients with myelodysplastic syndrome (MDS) remains unclear.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: